{"entity":{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","aka":[],"tldr":"IDEAYA Biosciences develops cancer drugs matched to the genetic make-up of a patient's tumour. Its most advanced drug, darovasertib, is in late-stage trials for a rare eye cancer called uveal melanoma.","summary":"IDEAYA Biosciences is a South San Francisco precision oncology company working on synthetic lethality, metabolic and epigenetic tumour dependencies. Its lead programme, darovasertib (a PKC inhibitor), is in phase 3 registrational trials in metastatic uveal melanoma and, with crizotinib, as adjuvant therapy in primary uveal melanoma (the OptimUM-11 trial with Servier dosed its first patient in September 2026), plus phase 2 studies in GNAQ/11-mutant tumours. Other programmes include IDE849, a DLL3-directed topoisomerase 1 antibody-drug conjugate in phase 1/2 for small cell lung cancer, for which the company reported FDA agreement on a phase 3 design in August 2026; IDE034 (B7H3/PTK7 ADC); IDE161 (PARG inhibitor); IDE397 (MAT2A inhibitor, phase 2) and IDE892 (PRMT5) for MTAP-deleted cancers; and IDE574 (KAT6/7). IDEAYA listed on Nasdaq in May 2019, raising 57.5 million US dollars gross in its IPO.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ideayabio.com/"},{"label":"Pipeline","url":"https://www.ideayabio.com/pipeline/"},{"label":"IPO closing press release (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex991.htm"},{"label":"Investor news releases","url":"https://ir.ideayabio.com/news-releases"}],"tags":[],"related":[],"cancers":["melanoma","sclc","pancreatic"],"sections":["targeted-therapy","adcs"],"technologies":["synthetic-lethality-approaches","adc","kinase-inhibitors"],"targets":["dll3"],"drugs":["darovasertib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05987332","nct03947385","nct05907954","nct07174583","nct06710847"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Later follow-on offerings and the GSK partnership were not sourced. Founding year not sourced. Pancreatic cancer tag rests on an August 2026 news headline about a Genentech clinical collaboration in MTAP-deleted KRAS G12D pancreatic cancer."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.ideayabio.com/","ticker":"IDYA","stage":"public","investors":[],"funding":[{"round":"IPO","year":2019,"amountUsd":57500000,"source":"https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex991.htm","note":"5.75 million shares at 10 US dollars, including full exercise of the underwriters' option"}]},"route":"/companies/ideaya-biosciences/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"target":[{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"}],"drug":[{"id":"darovasertib","kind":"drug","name":"Darovasertib","route":"/drugs/darovasertib/"}],"trial":[{"id":"nct05907954","kind":"trial","name":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","route":"/trials/nct05907954/"},{"id":"nct07174583","kind":"trial","name":"A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer","route":"/trials/nct07174583/"},{"id":"nct06710847","kind":"trial","name":"A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","route":"/trials/nct06710847/"},{"id":"nct05987332","kind":"trial","name":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","route":"/trials/nct05987332/"},{"id":"nct07015190","kind":"trial","name":"Neoadjuvant Darovasertib in Primary Uveal Melanoma","route":"/trials/nct07015190/"},{"id":"nct07804186","kind":"trial","name":"Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma","route":"/trials/nct07804186/"},{"id":"nct03947385","kind":"trial","name":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","route":"/trials/nct03947385/"}]}}